Table 2 Univariate and multivariate analyses of the overall survival of patients
Prognostic variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
HR (95% CI) | p value | HR (95% CI) | p value | |
Gender (female vs. male) | 0.712 (0.279–1.812) | 0.476 |  |  |
Stage (I-II vs. III-IV) | 2.625 (1.043–6.604) | 0.04 | 1.159 (0.253–5.311) | 0.849 |
B symphony (with vs. without) | 1.234 (0.512–2.973) | 0.64 |  |  |
IPI | 2.595 (1.073–6.277) | 0.034 | 0.565 (0.118–2.712) | 0.476 |
Final recurrence status | 3.346 (1.364–8.204) | 0.008 | 2.705 (0.941–7.776) | 0.065 |
MTV | 2.069 (0.843–5.078) | 0.112 |  |  |
ctDNA concentration | 2.975 (0.984–8.997) | 0.053 |  |  |
EBV-DNA level | 3.672 (1.396–9.664) | 0.008 | 3.174 (1.091–9.231) | 0.034 |
KMT2D mutation (without vs. with) | 0.289 (0.119–0.702) | 0.006 | 0.266 (0.086–0.828) | 0.022 |
APC mutation (without vs. with) | 0.550 (0.16–1.895) | 0.344 |  |  |
ATM mutation (without vs. with) | 0.271 (0.098–0.752) | 0.012 | 0.212 (0.064–0.700) | 0.011 |
ASXL3 mutation (without vs. with) | 2613 (0.347–19.68) | 0.351 |  |  |
JAK3 mutation (without vs. with) | 0.569 (0.166–1.949) | 0.369 |  |  |
SETD2 mutation (without vs. with) | 0.804 (0.184–3.507) | 0.771 |  |  |
TP53 mutation (without vs. with) | 0.615 (0.179–2.115) | 0.441 |  |  |
NOTCH1 mutation (without vs. with) | 0.410 (0.120–1.406) | 0.156 |  |  |